Stocks and Investing
Stocks and Investing
Mon, November 20, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Reiterated (SPRB) at Strong Buy and Held Target at $10 on, Nov 20th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Spruce Biosciences, Inc." (SPRB) at Strong Buy and Held Target at $10 on, Nov 20th, 2023.
Raghuram has made no other calls on SPRB in the last 4 months.
There are 4 other peers that have a rating on SPRB. Out of the 4 peers that are also analyzing SPRB, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Raghuram
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Wednesday, September 13th, 2023
- Joseph Schwartz of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $9 on, Friday, September 8th, 2023
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $7 on, Friday, August 18th, 2023
- Jonathan Wolleben of "JMP Securities" Maintained at Buy with Increased Target to $8 on, Wednesday, August 16th, 2023
Contributing Sources